Developer docs
API playgroundTry for free, no card

Search company profiles

Link Cell Therapies

Full company profile

uuid0008ag9

Namestring
Link Cell Therapies
Legal namestring
Link Cell Therapies, Inc.
Websiteurl
linkcelltx.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Link Cell Therapies is a clinical-stage biotechnology company founded in May 2022 by Stanford professors Robbie Majzner, MD and Crystal Mackall, MD to develop next-generation CAR-T cell therapies for solid tumors, which have historically been inaccessible to conventional CAR-T approaches due to lack of tumor-specific antigens and on-target/off-tumor toxicity. Headquartered in South San Francisco, California, the company has raised $92 million in total funding across a $12M seed round (May 2022, led by Samsara BioCapital and Sheatree Capital) and a $60M Series A (December 2025, led by Johnson & Johnson Innovation – JJDC), with additional participation from Bristol Myers Squibb, Kyowa Kirin, Wing Venture Capital, and Sherpa Healthcare Partners. Link emerged from stealth publicly in December 2025 alongside the Series A close and entered strategic collaborations with Janssen Biotech (Johnson & Johnson) and Nona Biosciences in January 2026.

The company's core platform is a proprietary AND-gate logic-gating CAR-T technology (LINK CAR) that engineers LAT and SLP-76 signaling molecules as surface receptors, requiring tumor cells to co-express two antigens before triggering T cell cytotoxicity — a design intended to spare healthy tissues expressing only single antigens. The platform is augmented by two complementary technologies: the ZAP platform (engages the ZAP-70 pathway to reduce T cell exhaustion) and the BOOST platform (amplifies CAR/TCR signaling to counter low target antigen expression). Lead clinical program LNK001 targets renal cell carcinoma with IND filing and Phase I initiation planned for 2026, and a second program targeting colorectal cancer is on track for Development Candidate selection in 2026 and human clinical studies in 2027. The team of 11–50 employees is led by COO Jerry Cacia (ex-Roche/Genentech 32 years, ex-Graphite Bio CTO) and CSO Mark Wallet, Ph.D. (ex-Century Therapeutics, ex-Fate Therapeutics).

Link Cell Therapies is pre-revenue with a hybrid business model: future revenue is expected from direct sale of CAR-T therapeutic products upon regulatory approval (one-time licensing of therapies to treatment centers) and from upfront payments, milestones, and royalties under strategic co-development partnerships with larger pharmaceutical companies such as Johnson & Johnson. Initial clinical distribution for LNK001 will occur through Phase I clinical trial sites, with broader commercialization dependent on pharma partnerships. The company's customer segments are organized by oncology use case, with solid tumors (renal cell carcinoma and colorectal cancer) as the primary focus and hematologic cancers as a secondary opportunity enabled by the same logic-gating technology.

Short descriptiontext

Link Cell Therapies is a clinical-stage biotechnology company developing next-generation CAR-T cell therapies for solid tumors using a proprietary AND-gate logic-gating platform that requires dual-antigen co-expression for tumor-specific cytotoxicity, targeting cancers including renal cell carcinoma and colorectal cancer.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CAR-T cell therapy, cell therapy platform, oncology therapeutics, solid tumor treatment, biopharmaceutical research
Industry2 codes
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
CAR-T Cell Therapy
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1CAR-T Therapeutic Products
TypeOne Time License
Description

Revenue will be generated from sale of CAR-T therapeutic products upon regulatory approval and commercialization. Programs target solid tumors (renal cell carcinoma, colorectal cancer) and hematologic cancers.

linkcelltx.com
2Licensing and Co-development Partnerships
TypeLicensing Royalties
Description

Strategic partnerships with pharmaceutical companies for co-development and commercialization of CAR-T therapies, generating upfront payments, milestone payments, and royalties.

linkcelltx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Link Cell Therapies develops next-generation CAR-T cell therapies for solid tumors and selected hematologic cancers using a proprietary AND-gate logic-gating platform that requires co-expression of two cancer antigens to trigger tumor cell killing while sparing healthy tissue. The company is advancing lead program LNK001 for renal cell carcinoma toward Phase I trials in 2026 and a second program for colorectal cancer toward human clinical studies in 2027, supported by ZAP and BOOST platform technologies that address T cell exhaustion and signaling evasion.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • LINK CAR T cells eradicated double-positive tumor cells and avoided single-antigen-positive cells in preclinical models, demonstrating improved safety compared to 2nd-generation CA9 CAR T cells for clear cell renal cell carcinoma
+1 more record
Product overview1 text field

Link Cell Therapies is a biotechnology company developing next-generation CAR-T cell therapies using a proprietary technology platform consisting of three interconnected components: the core LINK CAR Technology Platform (AND-gate logic-gating system), the ZAP Platform (reduces T cell exhaustion), and the BOOST Platform (amplifies signaling). The company's lead product LNK001 targets renal cell carcinoma and is advancing toward Phase I clinical trials in 2026. A second program targets colorectal cancer with clinical studies planned for 2027. Additional CAR-T programs for solid and liquid cancers are in earlier development stages.

Product and service2 records
1LNK001
CategoryClinical-stage CAR-T therapy program
Description

Lead CAR-T therapy program developed by Link Cell Therapies targeting renal cell carcinoma (RCC) using a dual-targeting AND-gated design that targets two antigens uniquely co-expressed in RCC tumors while avoiding on-target, off-tumor toxicity. On track for IND application and Phase I clinical trial initiation in 2026.

2Colorectal Cancer Program
CategoryClinical-stage CAR-T therapy program
Description

Second CAR-T therapy program at Link Cell Therapies targeting colorectal cancer using the proprietary logic-gating AND-gate design. Development Candidate selection is planned for 2026, with human clinical studies planned to begin in 2027.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-09
Description

Multi-target antibody discovery collaboration leveraging Nona's HCAb Harbour Mice platform and NonaCarFx screening technology alongside Link's logic-gated LINK CAR signaling technology. Aims to develop fully human heavy chain-only antibodies to reduce immunogenicity and enhance CAR design versatility.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-01-09
Description

Strategic collaboration to develop AND-gate CAR T programs for clinical use. Leverages Link's proprietary LINK logic gate technology to selectively target proteins co-expressed on tumor cells. Legal entity of Johnson & Johnson for this collaboration.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Allogene is a clinical-stage CAR-T cell therapy company developing allogeneic 'off-the-shelf' therapies for hematologic and solid tumors. Several Link executives (Diego Vargas, Regina Lin, Bryan Smith) came directly from Allogene, making it the closest comparable in CAR-T modality and target class.

2Arsenal Biosciences
TypeDirect peer
Description

Arsenal Bio develops logic-gated cell therapies for solid tumors using a programmable CAR-T approach. Bryan Smith (Link's Associate Director of Target Discovery) joined Link directly from Arsenal, indicating Arsenal is the most direct peer in the AND-gate/logic-gated solid tumor CAR-T niche.

TypeDirect peer
Description

Fate Therapeutics develops iPSC-derived NK and T cell therapies for cancer. Mark Wallet (Link's CSO) previously led translational science at Fate, and Link's iPSC-adjacent cell engineering approach is directly comparable in modality and indication.

TypeDirect peer
Description

Century Therapeutics develops gene-edited iPSC-derived CAR-NK and CAR-T therapies for cancer. Mark Wallet (Link CSO) was previously VP/Head of Immuno-oncology at Century, and the companies share gene-edited cell therapy modality and oncology focus.

5CARGO Therapeutics
TypeDirect peer
Description

CARGO Therapeutics develops CAR-T cell therapies for solid and hematologic cancers, with Abe Bassan (Link's President and Samsara principal) also serving on CARGO's board. Both are Samsara-backed CAR-T developers targeting solid tumor challenges.

TypeDirect peer
Description

Adaptimmune develops engineered T cell receptor (TCR-T) therapies for solid tumors, with an approved therapy (Tecelra) for synovial sarcoma. They compete in the same solid tumor adoptive cell therapy category as Link's CAR-T programs.

TypeDirect peer
Description

Cellectis is a clinical-stage gene-edited allogeneic CAR-T company developing TALEN-engineered cell therapies for hematologic and solid tumors. Comparable as a gene-engineering platform CAR-T developer targeting solid tumor challenges.

TypeDirect peer
Description

Precision BioSciences develops in vivo and ex vivo gene-edited cell therapies using ARCUS meganuclease technology, with oncology CAR-T programs for both hematologic and solid tumors. Comparable in gene-edited cell therapy modality.

TypeBroad incumbent
Description

CRISPR Therapeutics is a leading clinical-stage gene-editing company with Casgevy (the first FDA-approved CRISPR therapy) and a deep pipeline of gene-edited CAR-T therapies for oncology. Comparable as a larger, more advanced gene-edited cell therapy platform competitor.

TypeEmerging player
Description

Caribou Biosciences develops allogeneic CAR-T cell therapies using CRISPR-based gene editing for hematologic malignancies and solid tumors. Comparable as a smaller, clinical-stage allogeneic CAR-T developer with overlapping modality and target space.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Link Cell Therapies

CAR-T Cell Therapylinkcelltx.com

Link Cell Therapies is a clinical-stage biotechnology company developing next-generation CAR-T cell therapies for solid tumors using a proprietary AND-gate logic-gating platform that requires dual-antigen co-expression for tumor-specific cytotoxicity, targeting cancers including renal cell carcinoma and colorectal cancer.

What Link Cell Therapies does

Link Cell Therapies is a clinical-stage biotechnology company founded in May 2022 by Stanford professors Robbie Majzner, MD and Crystal Mackall, MD to develop next-generation CAR-T cell therapies for solid tumors, which have historically been inaccessible to conventional CAR-T approaches due to lack of tumor-specific antigens and on-target/off-tumor toxicity. Headquartered in South San Francisco, California, the company has raised $92 million in total funding across a $12M seed round (May 2022, led by Samsara BioCapital and Sheatree Capital) and a $60M Series A (December 2025, led by Johnson & Johnson Innovation – JJDC), with additional participation from Bristol Myers Squibb, Kyowa Kirin, Wing Venture Capital, and Sherpa Healthcare Partners. Link emerged from stealth publicly in December 2025 alongside the Series A close and entered strategic collaborations with Janssen Biotech (Johnson & Johnson) and Nona Biosciences in January 2026.

The company's core platform is a proprietary AND-gate logic-gating CAR-T technology (LINK CAR) that engineers LAT and SLP-76 signaling molecules as surface receptors, requiring tumor cells to co-express two antigens before triggering T cell cytotoxicity — a design intended to spare healthy tissues expressing only single antigens. The platform is augmented by two complementary technologies: the ZAP platform (engages the ZAP-70 pathway to reduce T cell exhaustion) and the BOOST platform (amplifies CAR/TCR signaling to counter low target antigen expression). Lead clinical program LNK001 targets renal cell carcinoma with IND filing and Phase I initiation planned for 2026, and a second program targeting colorectal cancer is on track for Development Candidate selection in 2026 and human clinical studies in 2027. The team of 11–50 employees is led by COO Jerry Cacia (ex-Roche/Genentech 32 years, ex-Graphite Bio CTO) and CSO Mark Wallet, Ph.D. (ex-Century Therapeutics, ex-Fate Therapeutics).

Link Cell Therapies is pre-revenue with a hybrid business model: future revenue is expected from direct sale of CAR-T therapeutic products upon regulatory approval (one-time licensing of therapies to treatment centers) and from upfront payments, milestones, and royalties under strategic co-development partnerships with larger pharmaceutical companies such as Johnson & Johnson. Initial clinical distribution for LNK001 will occur through Phase I clinical trial sites, with broader commercialization dependent on pharma partnerships. The company's customer segments are organized by oncology use case, with solid tumors (renal cell carcinoma and colorectal cancer) as the primary focus and hematologic cancers as a secondary opportunity enabled by the same logic-gating technology.

Link Cell Therapies firmographics

Firmographics
Name
Link Cell Therapies
Legal name
Link Cell Therapies, Inc.
Website
https://linkcelltx.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Link Cell Therapies is a clinical-stage biotechnology company developing next-generation CAR-T cell therapies for solid tumors using a proprietary AND-gate logic-gating platform that requires dual-antigen co-expression for tumor-specific cytotoxicity, targeting cancers including renal cell carcinoma and colorectal cancer.
Ownership category
akta.pro rank

Link Cell Therapies industry classification

Industry
Product category
CAR-T Cell Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • CAR-T cell therapy
  • Cell therapy platform
  • Oncology therapeutics
  • Solid tumor treatment
  • Biopharmaceutical research

Where Link Cell Therapies is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Link Cell Therapies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. CAR-T Therapeutic Products: Revenue will be generated from sale of CAR-T therapeutic products upon regulatory approval and commercialization. Programs target solid tumors (renal cell carcinoma, colorectal cancer) and hematologic cancers.
  2. Licensing and Co-development Partnerships: Strategic partnerships with pharmaceutical companies for co-development and commercialization of CAR-T therapies, generating upfront payments, milestone payments, and royalties.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Link Cell Therapies product offering

Product offering

Core offering

Link Cell Therapies develops next-generation CAR-T cell therapies for solid tumors and selected hematologic cancers using a proprietary AND-gate logic-gating platform that requires co-expression of two cancer antigens to trigger tumor cell killing while sparing healthy tissue. The company is advancing lead program LNK001 for renal cell carcinoma toward Phase I trials in 2026 and a second program for colorectal cancer toward human clinical studies in 2027, supported by ZAP and BOOST platform technologies that address T cell exhaustion and signaling evasion.

Product overview

Link Cell Therapies is a biotechnology company developing next-generation CAR-T cell therapies using a proprietary technology platform consisting of three interconnected components: the core LINK CAR Technology Platform (AND-gate logic-gating system), the ZAP Platform (reduces T cell exhaustion), and the BOOST Platform (amplifies signaling). The company's lead product LNK001 targets renal cell carcinoma and is advancing toward Phase I clinical trials in 2026. A second program targets colorectal cancer with clinical studies planned for 2027. Additional CAR-T programs for solid and liquid cancers are in earlier development stages.

Differentiator

Problem solved

Functional benefit

Products and services

  • LNK001 Lead CAR-T therapy program developed by Link Cell Therapies targeting renal cell carcinoma (RCC) using a dual-targeting AND-gated design that targets two antigens uniquely co-expressed in RCC tumors while avoiding on-target, off-tumor toxicity. On track for IND application and Phase I clinical trial initiation in 2026.
  • Colorectal Cancer Program Second CAR-T therapy program at Link Cell Therapies targeting colorectal cancer using the proprietary logic-gating AND-gate design. Development Candidate selection is planned for 2026, with human clinical studies planned to begin in 2027.

Quantifiable outcome

  • LINK CAR T cells eradicated double-positive tumor cells and avoided single-antigen-positive cells in preclinical models, demonstrating improved safety compared to 2nd-generation CA9 CAR T cells for clear cell renal cell carcinoma
  • +1 more outcomes

Companies that use Link Cell Therapies

Customer profile

Segments2 records

Ideal customer profiles2 records

Link Cell Therapies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Link Cell Therapies partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and flagship.

  • Nona BiosciencescoreTechnology or Integration · 9 January 2026Multi-target antibody discovery collaboration leveraging Nona's HCAb Harbour Mice platform and NonaCarFx screening technology alongside Link's logic-gated LINK CAR signaling technology. Aims to develop fully human heavy chain-only antibodies to reduce immunogenicity and enhance CAR design versatility.
  • Janssen Biotech, Inc.flagshipStrategic or Co-development Partner · 9 January 2025Strategic collaboration to develop AND-gate CAR T programs for clinical use. Leverages Link's proprietary LINK logic gate technology to selectively target proteins co-expressed on tumor cells. Legal entity of Johnson & Johnson for this collaboration.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Link Cell Therapies competitors and assessment

Company assessment

Direct peers

  • Allogene Therapeutics: Allogene is a clinical-stage CAR-T cell therapy company developing allogeneic 'off-the-shelf' therapies for hematologic and solid tumors. Several Link executives (Diego Vargas, Regina Lin, Bryan Smith) came directly from Allogene, making it the closest comparable in CAR-T modality and target class.
  • Arsenal Biosciences: Arsenal Bio develops logic-gated cell therapies for solid tumors using a programmable CAR-T approach. Bryan Smith (Link's Associate Director of Target Discovery) joined Link directly from Arsenal, indicating Arsenal is the most direct peer in the AND-gate/logic-gated solid tumor CAR-T niche.
  • Fate Therapeutics: Fate Therapeutics develops iPSC-derived NK and T cell therapies for cancer. Mark Wallet (Link's CSO) previously led translational science at Fate, and Link's iPSC-adjacent cell engineering approach is directly comparable in modality and indication.
  • Century Therapeutics: Century Therapeutics develops gene-edited iPSC-derived CAR-NK and CAR-T therapies for cancer. Mark Wallet (Link CSO) was previously VP/Head of Immuno-oncology at Century, and the companies share gene-edited cell therapy modality and oncology focus.
  • CARGO Therapeutics: CARGO Therapeutics develops CAR-T cell therapies for solid and hematologic cancers, with Abe Bassan (Link's President and Samsara principal) also serving on CARGO's board. Both are Samsara-backed CAR-T developers targeting solid tumor challenges.
  • Adaptimmune: Adaptimmune develops engineered T cell receptor (TCR-T) therapies for solid tumors, with an approved therapy (Tecelra) for synovial sarcoma. They compete in the same solid tumor adoptive cell therapy category as Link's CAR-T programs.
  • Cellectis: Cellectis is a clinical-stage gene-edited allogeneic CAR-T company developing TALEN-engineered cell therapies for hematologic and solid tumors. Comparable as a gene-engineering platform CAR-T developer targeting solid tumor challenges.
  • Precision BioSciences: Precision BioSciences develops in vivo and ex vivo gene-edited cell therapies using ARCUS meganuclease technology, with oncology CAR-T programs for both hematologic and solid tumors. Comparable in gene-edited cell therapy modality.

Broad incumbents

  • CRISPR Therapeutics: CRISPR Therapeutics is a leading clinical-stage gene-editing company with Casgevy (the first FDA-approved CRISPR therapy) and a deep pipeline of gene-edited CAR-T therapies for oncology. Comparable as a larger, more advanced gene-edited cell therapy platform competitor.

Emerging players

  • Caribou Biosciences: Caribou Biosciences develops allogeneic CAR-T cell therapies using CRISPR-based gene editing for hematologic malignancies and solid tumors. Comparable as a smaller, clinical-stage allogeneic CAR-T developer with overlapping modality and target space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Link Cell Therapies social profiles

Digital presence

Link Cell Therapies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Link Cell Therapies leadership team

Management profile

Number of profiles

Profiles13 records

Link Cell Therapies funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Link Cell Therapies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Link Cell Therapies

What does Link Cell Therapies do?

Link Cell Therapies develops next-generation CAR-T cell therapies for solid tumors and selected hematologic cancers using a proprietary AND-gate logic-gating platform that requires co-expression of two cancer antigens to trigger tumor cell killing while sparing healthy tissue. The company is advancing lead program LNK001 for renal cell carcinoma toward Phase I trials in 2026 and a second program for colorectal cancer toward human clinical studies in 2027, supported by ZAP and BOOST platform technologies that address T cell exhaustion and signaling evasion.

Is Link Cell Therapies a public or private company?

Link Cell Therapies is a private company. It is classified as venture growth investor backed and is currently operating.

When was Link Cell Therapies founded?

Link Cell Therapies was founded in 2022. It employs 11 to 50 people.

Where is Link Cell Therapies based?

Link Cell Therapies is headquartered in South San Francisco, United States, in the North America region.

How does Link Cell Therapies make money?

Two revenue lines are on record. CAR-T Therapeutic Products are the primary driver. The others are licensing and Co-development Partnerships.

Who are Link Cell Therapies's main competitors?

Direct peers on record are Allogene Therapeutics, Arsenal Biosciences, Fate Therapeutics, Century Therapeutics, CARGO Therapeutics, Adaptimmune, Cellectis and Precision BioSciences. CRISPR Therapeutics is listed as a broad incumbent. Caribou Biosciences is listed as an emerging player.

Does Link Cell Therapies have an API?

No public API is recorded for Link Cell Therapies.

What industry is Link Cell Therapies in?

Link Cell Therapies's product category is CAR-T Cell Therapy. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinSMEsLink Cell Therapies Raises $30M; Upsizes Series A to $90MLink Cell Therapies raised $30M to expand its Series A financing to $90M, led by Johnson & Johnson Innovation. The company initiated clinical dosing for its lead program LNK001 in clear cell renal cell carcinoma at MD Anderson. It plans a first-in-human trial for colorectal cancer in 2027.citybizLink Cell Therapies Begins CAR-T Trial, Expands Series A to $90 MillionLink Cell Therapies initiated clinical dosing of its lead logic-gated CAR-T therapy LNK001 in a Phase 1 study at MD Anderson for renal cell carcinoma. The company expanded its Series A financing to $90 million and added senior executives, including CEO Jie D'Elia. It plans a colorectal cancer program in 2027.BioSpaceLink Cell Therapies Initiates Clinical Dosing with Logic-Gated CAR-T Therapy, Expands Executive Leadership, and Upsizes Series A Financing to $90 MillionLink Cell Therapies initiated clinical dosing of its lead logic-gated CAR-T therapy LNK001 for advanced clear cell renal cell carcinoma at MD Anderson. The company also added three executives and upsized its Series A financing to $90 million, with a second colorectal cancer program planned for 2027.PR Newswire APACLink Cell Therapies Initiates Clinical Dosing with Logic-Gated CAR-T Therapy, Expands Executive Leadership, and Upsizes Series A Financing to $90 MillionLink Cell Therapies initiated clinical dosing of its lead CAR-T therapy LNK001 for advanced clear cell renal cell carcinoma at MD Anderson. The company added three executives and upsized its Series A financing to $90 million, with a second colorectal cancer trial planned for 2027.Venture Capital Access OnlineLink Cell Therapies Initiates Clinical Dosing with Logic-Gated CAR-T Therapy, Expands Executive Leadership, and Upsizes Series A Financing to $90 MillionLink Cell Therapies initiated clinical dosing of its lead CAR-T therapy LNK001 in advanced clear cell renal cell carcinoma at MD Anderson. The company added three executives and upsized its Series A financing to $90 million, with a second colorectal cancer trial planned for 2027.PR NewswireLink Cell Therapies Initiates Clinical Dosing with Logic-Gated CAR-T Therapy, Expands Executive Leadership, and Upsizes Series A Financing to $90 MillionLink Cell Therapies initiated clinical dosing of its lead logic-gated CAR-T therapy LNK001 for advanced clear cell renal cell carcinoma at MD Anderson. The company added three executives and upsized its Series A financing to $90 million, with a second colorectal cancer trial planned for 2027.Express Press Release DistributionGene Editing Market growth driven by CRISPR innovation and biotech investmentsThe global gene editing market is projected to grow from USD 5.87 billion in 2025 to USD 18.55 billion by 2033, expanding at a compound annual growth rate of 15.71%, with North America holding the largest regional market share of 52.65%. CRISPR-Cas technology dominates the market with a 75.32% share by technology, driven by its simplicity, efficiency, and versatility in research and clinical applications. The market expansion is being fueled by increased investments in precision medicine, with companies such as Addition Therapeutics securing USD 100 million and Link Cell Therapies raising USD 60 million to advance gene therapy platforms.PR NewswireNona Biosciences Enters into Collaboration Agreement with Link Cell Therapies to Advance CAR-T Cell TherapiesNona Biosciences has entered into a multi-target antibody discovery collaboration with Link Cell Therapies to advance CAR-T cell therapies for both solid and hematologic malignancies. The collaboration will leverage Nona's proprietary HCAb Harbour Mice® platform and NonaCarFx™ screening technology alongside Link Cell Therapies' logic-gated LINK CAR signaling technology. The partnership aims to develop fully human heavy chain-only antibodies that could reduce immunogenicity and enhance CAR design versatility.FinSMEsLink Cell Therapies Raises $60M in Series A FinancingLink Cell Therapies raised $60M in Series A funding led by Johnson & Johnson, with participation from founding investors. The company will use the funds to expand operations and R&D, including its lead program LNK001 for renal cell carcinoma, targeting an IND application in 2026. A colorectal cancer program is in development for 2026-2027.PR NewswireLink Cell Therapies Launches with Vision of Advancing CAR-T Therapies in Solid and Liquid TumorsLink Cell Therapies officially launched from stealth with a $60 million Series A financing round led by Johnson & Johnson Innovation – JJDC, Inc., bringing the company's total capital raised to $92 million across seed and Series A rounds. The oncology cell therapy company is developing proprietary logic-gating CAR-T technologies for solid and liquid tumors, with its lead program LNK001 for renal cell carcinoma on track for an Investigational New Drug application and Phase I clinical trial initiation in 2026. Link was founded in 2022 by researchers from Stanford University and the Dana-Farber Cancer Institute.